Trusted by:

clients clients clients clients clients clients clients clients clients clients
17-Sep-2024 1:30 PM EDT
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
University of Texas MD Anderson Cancer Center

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

Newswise: LJI discovery paves the way for antivirals against Ebola virus and its deadly relatives
Released: 17-Sep-2024 5:05 PM EDT
LJI discovery paves the way for antivirals against Ebola virus and its deadly relatives
La Jolla Institute for Immunology

The new study, led by researchers in the Saphire Lab at LJI, reveals the inner workings of the Ebola virus nucleocapsid. LA JOLLA, CA—At this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.

Newswise: one-of-the-fastest-ocean-currents-is-remarkably-stable-study-finds-940x529.jpeg
Released: 17-Sep-2024 4:05 PM EDT
One of the world's fastest ocean currents is remarkably stable, study finds
University of Miami

New study challenges previous assertions of Gulf Stream slowdown

Newswise: FDA approval of new drug regimen helps reduce risk of breast cancer recurrence for patients with early-stage disease
Released: 17-Sep-2024 4:05 PM EDT
FDA approval of new drug regimen helps reduce risk of breast cancer recurrence for patients with early-stage disease
University of California, Los Angeles (UCLA), Health Sciences

Teri Boudreaux was one of more than 5,000 women who joined a clinical trial that was looking at the benefit of adding the targeted therapy drug ribociclib to conventional hormonal therapy for the adjuvant treatment of HR-positive, HER2-negative early-stage breast cancer. I

Released: 17-Sep-2024 4:05 PM EDT
How Targeting 'Zombie Cells' Could Help Extend Healthspan
Hevolution Foundation

What if a drug could help you live a longer, healthier life? Scientists at the University of Connecticut are working on it. In a new study in Cell Metabolism, researchers described how to target specific cells to extend the lifespan and improve the health of mice late in life.

   
Newswise: Mapping Out Matter’s Building Blocks in 3D
Released: 17-Sep-2024 3:30 PM EDT
Mapping Out Matter’s Building Blocks in 3D
Thomas Jefferson National Accelerator Facility

Deep inside what we perceive as solid matter, the landscape is anything but stationary. The interior of the building blocks of the atom’s nucleus — particles called hadrons that most of us would recognize as protons and neutrons — are made up of a seething mixture of interacting quarks and gluons, known collectively as partons. The HadStruc collaboration has now come together to map out these partons and disentangle how they interact to form hadrons. Their latest findings were recently published in the Journal of High Energy Physics.

Released: 17-Sep-2024 3:05 PM EDT
Central America could play troubling new role in cocaine trade
Ohio State University

For many decades, the coca plant – the main ingredient in cocaine – has been grown almost exclusively in South America. But a new study shows that nearly half of northern Central America appears to be highly suitable for cultivating this lucrative cash crop.

Newswise: Wistar Institute Researchers Identify Parkinson-related Protein’s Role in Cancer and T Cell Activation
Released: 17-Sep-2024 2:05 PM EDT
Wistar Institute Researchers Identify Parkinson-related Protein’s Role in Cancer and T Cell Activation
Wistar Institute

Wistar scientists have demonstrated the role of Parkin — a protein implicated in Parkinson's disease — in the body’s innate immune response to cancer.

Newswise: Scientists at The Wistar Institute Clone Several New Anti-Interferon Antibodies - Developing Future Therapeutic Candidates with Broad Application Potential
Released: 17-Sep-2024 2:05 PM EDT
Scientists at The Wistar Institute Clone Several New Anti-Interferon Antibodies - Developing Future Therapeutic Candidates with Broad Application Potential
Wistar Institute

Wistar Institute scientists have successfully isolated and cloned fully human antibodies that can block specific Type-I interferon molecules in vitro; their discovery has an array of potential clinical & research applications, enabling scientists with a new way to investigate the role of specific Type-I interferons in a variety of diseases.

   
Newswise: Two common surgeries equally effective for treating blinding condition of the eyelid
10-Sep-2024 4:05 PM EDT
Two common surgeries equally effective for treating blinding condition of the eyelid
NIH, National Eye Institute (NEI)

Trachomatous trichiasis, a potentially blinding condition where inward-turned eyelashes scratch the front of the eye, can successfully be treated by either of the two most common types of eyelid surgery, according to findings from a large comparison trial funded by the National Institutes of Health.


close
1.77557